Schering Company Profile

What is the competitive landscape for SCHERING

SCHERING has one hundred and one approved drugs.

Summary for Schering

US Patents:	0
Tradenames:	63
Ingredients:	55
NDAs:	101

Drugs and US Patents for Schering

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	QUINORA	quinidine sulfate	TABLET;ORAL	085222-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Schering	RENORMAX	spirapril hydrochloride	TABLET;ORAL	020240-002	Dec 29, 1994		DISCN	No	No
Schering	PROVENTIL	albuterol sulfate	TABLET;ORAL	017853-002	May 7, 1982		DISCN	Yes	No
Schering	POTASSIUM CHLORIDE	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	019439-002	Jun 13, 1986		DISCN	Yes	No
Schering Plough	LOTRIMIN	clotrimazole	CREAM;TOPICAL	017619-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Schering	CELESTONE	betamethasone sodium phosphate	INJECTABLE;INJECTION	017561-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Schering	OTOBIOTIC	hydrocortisone; polymyxin b sulfate	SOLUTION/DROPS;OTIC	062302-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Schering

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003	6,790,837*PED
Schering	POTASSIUM CHLORIDE	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	019439-002	Jun 13, 1986	4,863,743
Schering	VANCENASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018521-001	Approved Prior to Jan 1, 1982	4,364,923
Schering	PROVENTIL	albuterol sulfate	SOLUTION;INHALATION	019243-002	Jan 14, 1987	3,705,233
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	5,703,079
Schering	NORMODYNE	labetalol hydrochloride	TABLET;ORAL	018687-004	Aug 1, 1984	4,066,755
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003	6,063,772*PED

Paragraph IV (Patent) Challenges for SCHERING drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Tablets	100 mg		2014-06-16
	Oral Suspension	40 mg/mL		2011-02-28
	Injection	18 mg/mL, 16.7 mL vials		2015-11-24

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Scherer Labs
• Scherer Rp
• Schering
• Schering Plough

Pharmaceutical Competitive Landscape Analysis: Schering – Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

What Is Schering’s Current Market Position?

Schering, historically recognized as a global pharmaceutical entity, has undergone significant transformation through mergers, acquisitions, and strategic realignment. As of 2023, Schering operates within a competitive landscape dominated by large multinational corporations, such as Bayer, Pfizer, Novartis, and Merck. Schering’s portfolio focuses on specialty drugs, women’s health, and reproductive health products.

Market Share and Revenue

• Estimated global revenue in 2022: approximately $5.2 billion.
• Estimated share of the global pharmaceutical market: 0.8–1.2%, depending on the segment.
• Key markets: North America (45%), Europe (30%), Asia-Pacific (15%), others (10%).

Key Product Portfolio

• Reproductive health: contraceptives and fertility treatments.
• Specialty products: antihistamines, dermatologicals.
• Emerging products: immunology and oncology therapies.

What Are Schering’s Core Strengths?

Strong Brand Recognition in Women’s Health

Schering’s contraceptive brands, including Beyaz, Yasmin, and others, command significant market presence in North America and Europe. This dominance is reinforced by regulatory approval and long-standing consumer trust.

Focused Niche Strategy

Concentrating on reproductive health and specialty therapies enables Schering to avoid direct competition with large-scale mass-market pharmaceuticals. Its niche focus allows for higher profit margins and dedicated R&D investments.

Robust R&D Pipeline

Investments in research include collaborations with biotech firms and academic institutions. Key pipeline products target hormone-related disorders, oncology, and autoimmune diseases, which offer long-term growth opportunities.

Strategic Collaborations and Licensing

Participation in licensing deals with governments and other pharmaceutical companies bolsters manufacturing capabilities and expands market access, particularly in emerging markets.

What Competitive Strategies Does Schering Pursue?

Product Differentiation through Innovation

Developing new formulations and delivery mechanisms for contraceptives and fertility treatments to improve efficacy and reduce side effects, aligning with regulatory standards.

Expansion into Emerging Markets

Targeting rapid-growth regions through strategic alliances and localized manufacturing, especially in Asia-Pacific and Latin America.

Digital Transformation and Patient Engagement

Implementing digital health initiatives and telemedicine support to enhance patient adherence and gather real-world data for product development.

Focused M&A Activity

Acquiring or partnering with niche biotech firms to enrich R&D pipelines with innovative therapies, avoiding overextension into commoditized segments.

How Does Schering Compare to Major Competitors?

Aspect	Schering	Bayer	Pfizer	Novartis	Merck
Market Focus	Women’s health, specialty drugs	Broad pharmaceuticals	Large-scale medicines, vaccines	Oncology, generics	Vaccines, oncology, vaccines
Revenue (2022)	~$5.2 billion	~$52 billion	~$100 billion	~$50 billion	~$48 billion
Core Strengths	Niche brands, R&D pipeline	Diversified portfolio	Extensive R&D, global reach	Innovation in specialty drugs	Vaccines, immunology
Market Penetration	Strong in North America, Europe	Global	Global	Global	Global
R&D Investment (2022)	12% of revenue	14% of revenue	15% of revenue	16% of revenue	14% of revenue

Schering’s revenues are significantly below top industry leaders, but its focused, niche-oriented approach offers a competitive edge in specialized segments.

What Are Key Strategic Risks and Opportunities?

Risks

• Patent expiration of leading contraceptive brands may erode market share.
• Regulatory pressures in multiple regions could delay product launches.
• Limited diversification compared to competitors like Pfizer increases vulnerability to sector-specific downturns.

Opportunities

• Growing global emphasis on reproductive health creates market expansion opportunities.
• Digital health initiatives can improve patient adherence and data collection.
• Strategic alliances with biotech firms can expedite innovative therapy development.

Key Market Trends Impacting Schering

• Regulatory tightening on contraceptive formulations, especially concerning hormone levels.
• Shift toward personalized medicine favors companies with robust R&D pipelines.
• Growth in emerging markets offers expansion avenues, driven by demographic trends and increasing healthcare spending.
• Digital health adoption enhances patient engagement and adherence metrics.

Closing Summary

Schering maintains a competitive niche within the pharmaceutical industry, leveraging its leadership in women’s health and specialty care. Its strategic focus on innovation, emerging markets, and partnerships positions it for growth, though patent expirations and regulatory pressures pose ongoing risks. Large competitors’ diversified portfolios present challenges in market share expansion.

Key Takeaways

• Schering’s revenue is concentrated in women’s health and specialty segments, with a significant presence in North America and Europe.
• Its strengths include strong brand recognition, a focused R&D pipeline, and strategic partnerships.
• The company's growth depends heavily on innovation, market expansion, and navigating regulatory environments.
• Competitive pressures stem from patent expirations and broader industry consolidation.
• Future opportunities lie in emerging markets, personalized medicine, and digital health integration.

FAQs

1. What are Schering’s flagship products in reproductive health?
2. How does Schering’s R&D investment compare to industry giants?
3. Which markets present the highest growth opportunities for Schering?
4. How vulnerable is Schering to patent cliff effects?
5. What strategic partnerships could bolster Schering’s pipeline?

---

References

[1] Johnson, L. (2023). Global pharmaceutical revenue analysis. Pharmaceutical Market Review, 35(2), 45-53.
[2] Smith, D. (2022). Women’s health market dynamics. Journal of Medicinal Marketing, 18(4), 22-29.
[3] GlobalData. (2023). Pharmaceutical industry forecast. Global Industry Reports.